Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pepsi fulfills Rockstar dream

This article was originally published in The Tan Sheet

Executive Summary

The Purchase, N.Y.-based beverage giant enters a multiyear agreement to distribute Rockstar energy drink, the No. 3 brand in the category, according to Information Resources Inc. sales data for the 52 weeks ending Jan. 25 from supermarkets, drugstores and mass merchandise outlets, excluding Wal-Mart. Rockstar, made by Rockstar International, sold $99.1 million during that period and captured 11 percent market share. A number of Pepsi energy drinks in the Amp line are in the top 20, but none claim more than 4 percent of the segment. The distribution deal, the terms of which were not disclosed, "is a major milestone" in Pepsi's bid to become the energy drink category leader, Hugh Johnston, president of Pepsi-Cola North America Beverages, says Feb. 19. Industry experts say to move up in the energy drink market, large firms must pursue deals like Pepsi's with Rockstar, given the "first mover advantage" of Red Bull and Hansen Natural's Monster (1"The Tan Sheet" Sept. 8, 2008, p. 11)

You may also be interested in...



Market Experts See Energy Drink Growth Flagging, Dominant Players Reigning

Beverage industry experts foresee the explosive growth rate of the energy drink market falling to earth during the next five years, as products have virtually saturated the market and new customer segments have failed to materialize

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102686

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel